MXPA06012232A - Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas. - Google Patents

Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas.

Info

Publication number
MXPA06012232A
MXPA06012232A MXPA06012232A MXPA06012232A MXPA06012232A MX PA06012232 A MXPA06012232 A MX PA06012232A MX PA06012232 A MXPA06012232 A MX PA06012232A MX PA06012232 A MXPA06012232 A MX PA06012232A MX PA06012232 A MXPA06012232 A MX PA06012232A
Authority
MX
Mexico
Prior art keywords
therapy
prediction
diagnosis
protein
plasma
Prior art date
Application number
MXPA06012232A
Other languages
English (en)
Inventor
Maher Albitar
Elihu H Estey
Hagop M Kantarjian
Francis J Giles
Michael J Keating
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MXPA06012232A publication Critical patent/MXPA06012232A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/25—Chemistry: analytical and immunological testing including sample preparation
    • Y10T436/25625—Dilution

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Optics & Photonics (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion demuestra que el diagnostico y prediccion del comportamiento clinico en pacientes con malignidades hematologicas, tal como leucemia, puede lograrse mediante analisis de proteinas presentes en una muestra de plasma; de este modo, en modalidades particulares, la presente invencion utiliza plasma para crear un diagnostico o pronostico del perfil de proteina de una malignidad hematologica que comprende recolectar muestras de plasma de una poblacion de pacientes con malignidades hematologicas; generar espectros de proteina de las muestras de plasma con o sin fraccionamiento; comparar los espectros de proteina con datos clinicos; e identificar marcadores de proteina en las muestras de plasma que se correlacionan con los datos clinicos; los marcadores de proteina identificados por este enfoque pueden entonces utilizarse para crear un perfil de proteina que puede utilizarse para diagnosticar la malignidad hematologica o determinar el pronostico de malignidad hematologica; potencialmente estas proteinas especificas pueden ser identificadas y senaladas en la terapia de estas malignidades.
MXPA06012232A 2004-04-20 2005-04-20 Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas. MXPA06012232A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US56387304P 2004-04-20 2004-04-20
PCT/US2005/013224 WO2005103719A2 (en) 2004-04-20 2005-04-20 Using plasma proteomic pattern for diagnosis, classification, prediction of response to therapy and clinical behavior, stratification of therapy, and monitoring disease in hematologic malignancies

Publications (1)

Publication Number Publication Date
MXPA06012232A true MXPA06012232A (es) 2007-06-15

Family

ID=35094386

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06012232A MXPA06012232A (es) 2004-04-20 2005-04-20 Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas.

Country Status (7)

Country Link
US (3) US7622306B2 (es)
EP (2) EP1756578A2 (es)
JP (1) JP4864875B2 (es)
BR (1) BRPI0509978A (es)
CA (1) CA2563847A1 (es)
MX (1) MXPA06012232A (es)
WO (1) WO2005103719A2 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756554A4 (en) * 2004-06-03 2009-04-29 Vermillion Inc BIOMARKERS FOR PERIPHERAL ARTERY DISEASE
US20070042443A1 (en) 2005-08-17 2007-02-22 Quest Diagnostics Investments Incorporated Hematopoietic cell phenotyping using free circulating cellular markers
JP2007240326A (ja) * 2006-03-08 2007-09-20 Intec Web & Genome Informatics Corp 波形解析装置
US20100140465A1 (en) * 2006-03-29 2010-06-10 Chulso Moon Apparatus and Method for Filtration to Enhance the Detection of Peaks
EP2109688A4 (en) * 2007-01-23 2010-02-17 Univ Virginia GALECTIN-3 BINDING PROTEIN AS BIOMARKER FOR HEART CIRCULATION DISEASES
WO2009022173A1 (en) * 2007-08-14 2009-02-19 Petscreen Limited Novel diagnostic methods
KR100937720B1 (ko) * 2009-04-20 2010-01-20 전남대학교산학협력단 ＣＦＨ 또는 ＡｐｏＨ를 급성골수성백혈병 관해 진단용 생화학적 마커로 사용하는 방법
JP2013535683A (ja) 2010-07-30 2013-09-12 イー・エム・デイー・ミリポア・コーポレイシヨン クロマトグラフィー媒体及び方法
CA2954425C (en) 2014-09-02 2019-05-07 Emd Millipore Corporation High surface area fiber media with nano-fibrillated surface features
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
CN109507347B (zh) * 2017-09-14 2021-01-29 湖南中烟工业有限责任公司 一种色谱峰选择方法
US11096582B2 (en) * 2018-11-20 2021-08-24 Veris Health Inc. Vascular access devices, systems, and methods for monitoring patient health
CN110632191B (zh) * 2019-09-10 2023-04-18 福建工程学院 一种基于决策树算法的变压器色谱峰定性方法和系统
EP4198511A1 (en) * 2021-12-17 2023-06-21 Lehtio, Janne Method for determining aml prognosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5534121A (en) 1994-05-16 1996-07-09 The United States Of America As Represented By The Department Of Health And Human Services Preparative two dimensional gel electrophoresis system
CA2341243A1 (en) 1998-08-31 2000-03-09 C.B.S. Scientific Co., Inc. Two dimensional gel electrophoresis system
IN191209B (es) 1999-09-08 2003-10-04 Council Scient Ind Res
EP1386275A2 (en) * 2000-07-18 2004-02-04 Correlogic Systems, Inc. A process for discriminating between biological states based on hidden patterns from biological data
AUPQ886100A0 (en) * 2000-07-19 2000-08-10 Biotron Limited Diagnostic test
US20030013120A1 (en) * 2001-07-12 2003-01-16 Patz Edward F. System and method for differential protein expression and a diagnostic biomarker discovery system and method using same
EP1506408A4 (en) * 2002-05-17 2007-07-11 Eastern Virginia Med School METHOD FOR DIAGNOSIS OF HTLV-I-MEDIATED DISEASES

Also Published As

Publication number Publication date
US7622306B2 (en) 2009-11-24
EP2221618A2 (en) 2010-08-25
US8097468B2 (en) 2012-01-17
JP4864875B2 (ja) 2012-02-01
WO2005103719A2 (en) 2005-11-03
BRPI0509978A (pt) 2007-10-16
US20060073527A1 (en) 2006-04-06
EP1756578A2 (en) 2007-02-28
US20120145891A1 (en) 2012-06-14
WO2005103719A3 (en) 2005-12-15
US20100063747A1 (en) 2010-03-11
EP2221618A3 (en) 2010-09-01
CA2563847A1 (en) 2005-11-03
US8563323B2 (en) 2013-10-22
JP2007533997A (ja) 2007-11-22

Similar Documents

Publication Publication Date Title
MXPA06012232A (es) Uso del patron proteogenomico del plasma para diagnostico, clasificacion, prediccion de respuesta a la terapia y comportamiento clinico, estratificacion de la terapia y monitoreo de enfermedad, en malignidades hematologicas.
Zhang et al. Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient
Drake et al. Serum, salivary and tissue proteomics for discovery of biomarkers for head and neck cancers
Srinivasan et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis
SG170061A1 (en) Biomarkers useful for diagnosing prostate cancer, and methods thereof
ATE490465T1 (de) Diagnose- und prognoseverfahren von blasenkrebs.
US9885085B2 (en) Apparatus, compositions, and methods for assessment of chronic obstructive pulmonary disease progression among rapid and slow decline conditions
HK1159249A1 (en) Kit for the identification of ovarian cancer protein biomarkers using proteomic techniques
IL182062A0 (en) Methods and computer program products for analysis and optimization of marker candidates for cancer prognosis
WO2005042761A3 (en) Biomarkers for amyotrophic lateral sclerosis
BRPI0311233B8 (pt) métodos in vitro para triagem de um paciente para carcinoma hepatocelular (hcc), e para diagnosticar hcc em um paciente, bem como método e kit para detectar ou determinar o nível de gpc3 em uma amostra
Florentinus et al. Identification and quantification of peptides and proteins secreted from prostate epithelial cells by unbiased liquid chromatography tandem mass spectrometry using goodness of fit and analysis of variance
TW200613734A (en) Detection and identification of peptide and protein modifications
Siciliano et al. Rapid peptidomic profiling of peritoneal fluid by MALDI-TOF mass spectrometry for the identification of biomarkers of endometriosis
WO2006002240A3 (en) Computer systems and methods for constructing biological classifiers and uses thereof
Gonzalez Novel biomarkers for hepatocellular carcinoma surveillance: has the future arrived?
WO2007126901A3 (en) Apparatus and method for predicting disease
CA2873632A1 (en) Srm/mrm assay for subtyping lung histology
DE602005013430D1 (de) Verwendung von asc als marker für kolorektalkarzinome
WO2003068268A3 (en) Treatment, diagnosis and imaging of disease
Matharoo‐Ball et al. Serum biomarker profiling in cancer studies: a question of standardisation?
Shau et al. Proteomic profiling of cancer biomarkers
DE602005027065D1 (de) Verwendung neuartiger biomarker zum nachweis von hodenkrebs in situ und abgeleiteten krebserkrankungen in menschlichen proben
Jin et al. 2‐D DIGE and MALDI‐TOF‐MS analysis of the serum proteome in human osteosarcoma
ATE534037T1 (de) Verwendung des proteins asc als marker für brustkrebs